AbbVie ABBV Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenues by Product | ||||||
| All other | $1.03B+66.1% | $617M-6.5% | $660M+9.5% | $603M-51.9% | $1.25B+66.6% | |
| Botox Cosmetic | $668M-6.8% | $717M+12.6% | $637M-7.9% | $692M+24.5% | $556M-19.1% | |
| Botox Therapeutic | $1.01B+1.9% | $990M+0.5% | $985M+6.1% | $928M+7.2% | $866M-0.8% | |
| Elahere | $198M+8.8% | $182M+7.1% | $170M+6.9% | $159M-11.2% | $179M+20.9% | |
| Epkinly | $83M+2.5% | $81M+17.4% | $69M-1.4% | $70M+37.3% | $51M+27.5% | |
| Humira | $688M-44.8% | $1.25B+25.5% | $993M-15.8% | $1.18B+5.3% | $1.12B-33.4% | |
| Imbruvica | $556M-17.1% | $671M-5.0% | $706M-6.4% | $754M+2.2% | $738M-13.0% | |
| Juvederm Collection | $232M-6.8% | $249M-1.6% | $253M-2.7% | $260M+12.6% | $231M-17.2% | |
| Linzess | $283M+61.7% | $175M-46.3% | $326M+26.4% | $258M+74.3% | $148M-36.5% | |
| Mavyret | $351M+8.3% | $324M+3.8% | $312M-16.8% | $375M+22.5% | $306M+5.2% | |
| Other Aesthetics | $286M-10.6% | $320M+5.6% | $303M-7.3% | $327M+3.8% | $315M-5.1% | |
| Other Neuroscience | $125M+166% | $47M+2.2% | $46M-16.4% | $55M-64.5% | $155M+177% | |
| Qulipta | $296M+2.8% | $288M0.0% | $288M+7.9% | $267M+38.3% | $193M-4.0% | |
| Rinvoq | $2.12B-10.7% | $2.37B+8.7% | $2.18B+7.7% | $2.03B+18.0% | $1.72B-6.3% | |
| Skyrizi | $4.48B-10.4% | $5.01B+6.3% | $4.71B+6.4% | $4.42B+29.1% | $3.43B-9.3% | |
| Ubrelvy | $339M0.0% | $339M-4.2% | $354M+4.7% | $338M+40.8% | $240M-20.8% | |
| Venclexta | $770M+8.5% | $710M-2.2% | $726M+5.1% | $691M+3.9% | $665M+1.5% | |
| Vraylar | $905M-11.4% | $1.02B+9.4% | $934M+3.8% | $900M+17.6% | $765M-17.2% | |
| Vyalev | $201M+9.8% | $183M+32.6% | $138M+40.8% | $98M+55.6% | $63M+43.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AbbVie break its business down?
- AbbVie (ABBV) reports net revenues by product across 19 parts — All other, Botox Cosmetic, Botox Therapeutic, Elahere and Epkinly. Each is extracted from the segment footnotes and tracked over time.
- Where does AbbVie's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AbbVie's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
